John T. Rudy
Member / Co-chair, Securities & Capital Markets Practice
+1.617.348.3050
John’s practice focuses on the representation of public and private companies and investment banks in capital markets transactions. He also advises public and private companies and investors in connection with mergers and acquisitions, equity and debt financings, and securities and general corporate matters.
Prior to joining Mintz, John was an associate at Davis Polk & Wardwell, LLP in New York and at Willkie Farr & Gallagher, LLP in New York and London.
John received his JD from the University of Pennsylvania Law School, where he was an associate editor of the Journal of International Economic Law. He also has a BSFS from Georgetown University School of Foreign Service.
John is admitted to practice in Massachusetts and New York.
viewpoints
SEC Proposed Rule: Opt in (or Out!) of Semiannual Reporting
May 6, 2026 | Alert | By Melanie Ruthrauff Levy, John T. Rudy , Anne Bruno, Daniel A. Bagliebter
Client alert on SEC’s proposed rule to allow publicly reporting companies to elect semiannual reporting on new Form 10-S in lieu of quarterly reports on Form 10-Q.
Frequently Asked Questions for Private Companies Considering a Reverse Merger
February 13, 2024 | Article | By William Hicks, John T. Rudy
Reverse mergers aren’t an alternative to an IPO, rather they can be a strategic approach for companies looking to go public by leveraging “fallen angels”. Mintz Members Bill Hicks and John Rudy answer frequently asked questions for private companies considering a reverse merger in an article featured in PitchBook’s 2023 Annual US VC Valuations Report. The authors detail the benefits and challenges associated with a reverse merger including finding partners, PIPE financing, Nasdaq access for non-US companies, and SEC implications.
News & Press
Mintz Advises on Verastem Oncology’s $250 Million Underwritten Offering
October 15, 2026|
Mintz Advises on Atrium Therapeutics’ $50 Million Private Placement
October 12, 2026|
Mintz Advises on Edesa Biotech’s $25 Million Public Offering
August 25, 2026|
Mintz Advises on uniQure’s $259 Million Public Offering
June 25, 2026|
Mintz Advises on Nyxoah’s $95 Million Public Offering
June 12, 2026|
Mintz Advises on ImageneBio’s $30 Million Private Placement
April 15, 2026|
Mintz Advises on Eupraxia Pharmaceuticals $63.2 Million Public Offering
February 27, 2026|
Mintz Advises on Protara Therapeutics' $75 Million Public Offering
December 16, 2025|
Mintz Advises on Fulcrum Therapeutics' $175 Million Public Offering
December 16, 2025|
Mintz Advises on Wave Life Sciences $402.5 Million Public Offering
December 12, 2025|
Mintz Advises on Capricor Therapeutics’ $150 Million Public Offering
December 10, 2025|
Mintz Advises on Verastem Oncology’s $103 Million Public Offering
November 21, 2025|
Mintz Advises on Eledon Pharmaceuticals’ $50 Million Follow-on Offering
November 20, 2025|
Mintz Advises on MoonLake Immunotherapeutics’ $75 Million Offering
November 12, 2025|
Mintz Advises on uniQure's $345 Million Public Offering
September 30, 2025|
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025|
Mintz Advises on Equillium, Inc.'s up to $50 Million PIPE
August 15, 2025|
Mintz Advises on $90 Million Underwritten Offering by Rezolute
April 25, 2025|
Mintz Advises Aspen Aerogels on $98M Follow-on Offering
November 19, 2024|
Mintz Advises ArriVent BioPharma on $175M Nasdaq IPO
February 1, 2024|
Companies Beef Up Risk Disclosures As Biden Era Begins
February 22, 2021|
Mintz Advises NexImmune in its Upsized $126.5 Million IPO
February 17, 2021|
Mintz Represents Viela Bio in its IPO
October 4, 2019|
Time Is Quickly Running Out for First Quarter‘s IPO Hopefuls
April 2, 2019|
Time Is Quickly Running Out for the First Quarter's IPO Hopefuls
January 24, 2019|
Mintz Elevates Eight Attorneys to Members of the Firm
May 13, 2014|
Four Mintz Attorneys Selected for Boston’s Future Leaders Program
February 12, 2014|
Events & Speaking
The Big Biotech IPO: Charting a Path Through Opportunities and Challenges
LSX World Congress London
London, UK
Disclosure, Financing, and Executive Compensation Basics for New and Aspiring Public Company Executives
Boston Bar Association
Webinar
Everything Life Sciences Companies Need to Know to Navigate the COVID-19 Pandemic
View the Webinar Recording
Recognition & Awards
Massachusetts Super Lawyers: Rising Star – Securities & Corporate Finance list (2013 – 2014, 2017 – 2019)
Greater Boston Chamber of Commerce: Boston’s Future Leaders (2014)
Chambers Massachusetts: Ranked in Capital Markets (2025 – 2026)
Chambers Massachusetts: Ranked in Life Sciences (2026)
Legal 500 United States: Recommended for Capital Markets – Equity (2026)
Recent Insights
Mintz Advises on Verastem Oncology’s $250 Million Underwritten Offering
October 15, 2026|
Mintz Advises on Atrium Therapeutics’ $50 Million Private Placement
October 12, 2026|
